The Skill to Heal. The Heart to Care.

Phone: 505.842.8171

dotAfter Hours: 505.857.3877

dotPharmacy: 505.822.3911

Latest Cancer News

Aromasin is New Treatment Option for Young Women With Hormone-sensitive Breast Cancer (08-19-2014)

The results of a recently completed clinical study presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and now published online in the New England Journal of Medicine demonstrate that Aromasin® (exemestane), is... Continue Reading

Scientific Review Suggests Aspirin Significantly Cuts Cancer Rates (08-18-2014)

A recent review of several studies confirms that taking a small daily dose of aspirin significantly reduces the risk of developing – or dying from several kinds of cancer.(1) Several clinical studies have suggested that aspirin can reduce the risk... Continue Reading

Weighing the Risks (08-12-2014)

Exploring the Link Between Obesity and Cancer By Kari Bohlke, ScD “For the great majority of Americans who do not use tobacco, weight control, dietary choices, and levels of physical activity are the most important modifiable determinants of cancer... Continue Reading

Large Independent Validation Study Validates Oncotype DX Prostate Cancer Test (08-11-2014)

Genomic Health, Inc. announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts... Continue Reading

Exposure to Some Inflammatory Bowel Disease Drugs May Increase Leukemia Risk (08-8-2014)

Thiopurines are an established treatment for inflammatory bowel disease (IBD) patients.  They are used to reduce inflammation and provide symptom relief.  Thiopurine immunosuppressive drugs have now been reported to increase the risk of acute myelod... Continue Reading

Kyprolis Improves Progression-Free Survival in Multiple Myeloma (08-7-2014)

Amgen announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE met its primary endpoint of progression-free survival (PFS).  Patients treated with Kyprolis® (carfilzomib) in combination with Revlimid® (lenalidomide)... Continue Reading


The  U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for Jakafi® (ruxolitinib) as a potential treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are... Continue Reading

Gilotrif combined with Erbitux Benefits Non-Small Cell Lung Cancer Patients Resistant to EGFR Inhibitors (08-5-2014)

Researchers recently reported that a combination of the epidermal growth factor receptor (EGFR) targeted agents Gilotrif® (afatinib) and Erbitux® (cetuximab) were able to effectively shrink EGFR positive non-small cell lung (NSCLC)cancer that had stopped... Continue Reading

Pembrolizumab Appears Promising in Treatment of Non-Small Cell Lung Cancer (08-4-2014)

Results from an ongoing Phase Ib study indicate that treatment with the experimental anti-PD-1 antibody pembrolizumab resulted in high response rates and slowed cancer progression in previously untreated stage IV non–small cell lung cancer (NSCLC).... Continue Reading

Hepatitis C Cases Could Be Cured By Novel Oral Drug Regimen (07-31-2014)

According to the results of two new clinical studies published in The Lancet, two new pill-only antiviral drug regimens for hepatitis C virus infection provide shorter and more effective treatment options with fewer side effects for most patients affected... Continue Reading

Largest Study to Date of Pembrolizumab in Advanced Melanoma Shows Promising Activity (07-31-2014)

The investigational anti-PD-1 antibody pembrolizumab is demonstrating promising survival rates among patients with advanced melanoma. Data from an ongoing Phase 1 trial of the drug were presented at the 50th Annual Meeting of the American Society of... Continue Reading

Investigational Drug Pembrolizumab Shows Anticancer Activity in Advanced Melanoma (07-30-2014)

Recent findings reported in The Lancet indicate that the investigational drug pembrolizumab may be effective in patients with advanced melanoma that has progressed after treatment with Yervoy® (ipilimumab).[1] These findings build on previous research... Continue Reading

Next Page »